Nocardia pneumonia is clinically known as pulmonary nocardiosis, and cotrimoxazole is the first choice for coping with the disease, and sensitive drugs may be selected on the basis of drug sensitivity tests in severe or refractory patients. Pulmonary Nocardiosis is a disease caused by Nocardia causing purulent granulomatous lesions in the lungs. Cotrimoxazole is the main and preferred drug for the treatment of pulmonary nocardiosis, and adult patients can be treated with this drug alone. However, in severe and refractory patients, sensitive drugs should be selected based on drug sensitivity tests, and a combination of drugs is generally recommended, with the regimen of cotrimoxazole + amikacin or + ceftriaxone or imipenem. The overall morbidity and mortality rate of pulmonary nocardiosis is 25%, and the prognosis of patients with bacteremia, hepatic and renal dissemination, etc. is poor; therefore, individuals should strive to diagnose and treat pulmonary nocardiosis as early as possible, and consult a doctor promptly if they have any abnormal physical discomfort. Drugs should be used under the guidance of a physician.